{"bundle_type":"pith_open_graph_bundle","bundle_version":"1.0","pith_number":"pith:2018:RVQHNDQNUI2RN5CDLNLJRR7ROQ","short_pith_number":"pith:RVQHNDQN","canonical_record":{"source":{"id":"1803.04397","kind":"arxiv","version":2},"metadata":{"license":"http://creativecommons.org/licenses/by/4.0/","primary_cat":"stat.ME","submitted_at":"2018-03-12T17:47:00Z","cross_cats_sorted":[],"title_canon_sha256":"0b8c9f1532d538f93166f74637f82cd6950933ac2d5f1e6501723e224ec5652e","abstract_canon_sha256":"a8c637a81373a2c0bb56210beaaa93028ac497f1bb7561d46256bc2d67c3f289"},"schema_version":"1.0"},"canonical_sha256":"8d60768e0da23516f4435b5698c7f17436a8635fccc884c81e7ae04ebdf1bf7b","source":{"kind":"arxiv","id":"1803.04397","version":2},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1803.04397","created_at":"2026-05-18T00:13:04Z"},{"alias_kind":"arxiv_version","alias_value":"1803.04397v2","created_at":"2026-05-18T00:13:04Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1803.04397","created_at":"2026-05-18T00:13:04Z"},{"alias_kind":"pith_short_12","alias_value":"RVQHNDQNUI2R","created_at":"2026-05-18T12:32:50Z"},{"alias_kind":"pith_short_16","alias_value":"RVQHNDQNUI2RN5CD","created_at":"2026-05-18T12:32:50Z"},{"alias_kind":"pith_short_8","alias_value":"RVQHNDQN","created_at":"2026-05-18T12:32:50Z"}],"events":[{"event_type":"record_created","subject_pith_number":"pith:2018:RVQHNDQNUI2RN5CDLNLJRR7ROQ","target":"record","payload":{"canonical_record":{"source":{"id":"1803.04397","kind":"arxiv","version":2},"metadata":{"license":"http://creativecommons.org/licenses/by/4.0/","primary_cat":"stat.ME","submitted_at":"2018-03-12T17:47:00Z","cross_cats_sorted":[],"title_canon_sha256":"0b8c9f1532d538f93166f74637f82cd6950933ac2d5f1e6501723e224ec5652e","abstract_canon_sha256":"a8c637a81373a2c0bb56210beaaa93028ac497f1bb7561d46256bc2d67c3f289"},"schema_version":"1.0"},"canonical_sha256":"8d60768e0da23516f4435b5698c7f17436a8635fccc884c81e7ae04ebdf1bf7b","receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-05-18T00:13:04.451074Z","signature_b64":"jIYlXrPDTZxmiCeZCp+nfefnNdnUzLUNErMi8meTmnQKSJXu1EX4dAbWo87qaP2oDN+qUMbmmdXMvGk18Ge7Bw==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"8d60768e0da23516f4435b5698c7f17436a8635fccc884c81e7ae04ebdf1bf7b","last_reissued_at":"2026-05-18T00:13:04.450429Z","signature_status":"signed_v1","first_computed_at":"2026-05-18T00:13:04.450429Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"source_kind":"arxiv","source_id":"1803.04397","source_version":2,"attestation_state":"computed"},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-18T00:13:04Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"A9zO/W+5ZsMitQHERpX1jg7iIHVp0qIZgPhz0/qSmzPLr3zreK3b1g8ouYJCWZyl1+r9I5v7WPkXzki9FGymCg==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-06-08T17:16:55.419448Z"},"content_sha256":"ac2dc5b4cd7e1b314c077c4d3fdd65093d8296b6ce23792b0648b81e92893625","schema_version":"1.0","event_id":"sha256:ac2dc5b4cd7e1b314c077c4d3fdd65093d8296b6ce23792b0648b81e92893625"},{"event_type":"graph_snapshot","subject_pith_number":"pith:2018:RVQHNDQNUI2RN5CDLNLJRR7ROQ","target":"graph","payload":{"graph_snapshot":{"paper":{"title":"An information-theoretic Phase I/II design for molecularly targeted agents that does not require an assumption of monotonicity","license":"http://creativecommons.org/licenses/by/4.0/","headline":"","cross_cats":[],"primary_cat":"stat.ME","authors_text":"Pavel Mozgunov, Thomas Jaki","submitted_at":"2018-03-12T17:47:00Z","abstract_excerpt":"For many years Phase I and Phase II clinical trials were conducted separately, but there was a recent shift to combine these Phases. While a variety of Phase~I/II model-based designs for cytotoxic agents were proposed in the literature, methods for molecularly targeted agents (TA) are just starting to develop. The main challenge of the TA setting is the unknown dose-efficacy relation that can have either an increasing, plateau or umbrella shape. To capture these, approaches with more parameters are needed to model the dose-efficacy relationship or, alternatively, more orderings of the dose-eff"},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1803.04397","kind":"arxiv","version":2},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"verdict_id":null},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-18T00:13:04Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"o+dw8WR6yqe07ZyIudp50BsCsQvpRWNCz8mL3vsomBVQMZbawYVxsA/g6L0aA7VltfL4yxJ1qNDhKrC4T2loDA==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-06-08T17:16:55.420187Z"},"content_sha256":"b8fd8d654d72f042d2b2f3db3bd06b8efeafaeb29ce13769d09f3dfd8c43aab0","schema_version":"1.0","event_id":"sha256:b8fd8d654d72f042d2b2f3db3bd06b8efeafaeb29ce13769d09f3dfd8c43aab0"}],"timestamp_proofs":[],"mirror_hints":[{"mirror_type":"https","name":"Pith Resolver","base_url":"https://pith.science","bundle_url":"https://pith.science/pith/RVQHNDQNUI2RN5CDLNLJRR7ROQ/bundle.json","state_url":"https://pith.science/pith/RVQHNDQNUI2RN5CDLNLJRR7ROQ/state.json","well_known_bundle_url":"https://pith.science/.well-known/pith/RVQHNDQNUI2RN5CDLNLJRR7ROQ/bundle.json","status":"primary"}],"public_keys":[{"key_id":"pith-v1-2026-05","algorithm":"ed25519","format":"raw","public_key_b64":"stVStoiQhXFxp4s2pdzPNoqVNBMojDU/fJ2db5S3CbM=","public_key_hex":"b2d552b68890857171a78b36a5dccf368a953413288c353f7c9d9d6f94b709b3","fingerprint_sha256_b32_first128bits":"RVFV5Z2OI2J3ZUO7ERDEBCYNKS","fingerprint_sha256_hex":"8d4b5ee74e4693bcd1df2446408b0d54","rotates_at":null,"url":"https://pith.science/pith-signing-key.json","notes":"Pith uses this Ed25519 key to sign canonical record SHA-256 digests. Verify with: ed25519_verify(public_key, message=canonical_sha256_bytes, signature=base64decode(signature_b64))."}],"merge_version":"pith-open-graph-merge-v1","built_at":"2026-06-08T17:16:55Z","links":{"resolver":"https://pith.science/pith/RVQHNDQNUI2RN5CDLNLJRR7ROQ","bundle":"https://pith.science/pith/RVQHNDQNUI2RN5CDLNLJRR7ROQ/bundle.json","state":"https://pith.science/pith/RVQHNDQNUI2RN5CDLNLJRR7ROQ/state.json","well_known_bundle":"https://pith.science/.well-known/pith/RVQHNDQNUI2RN5CDLNLJRR7ROQ/bundle.json"},"state":{"state_type":"pith_open_graph_state","state_version":"1.0","pith_number":"pith:2018:RVQHNDQNUI2RN5CDLNLJRR7ROQ","merge_version":"pith-open-graph-merge-v1","event_count":2,"valid_event_count":2,"invalid_event_count":0,"equivocation_count":0,"current":{"canonical_record":{"metadata":{"abstract_canon_sha256":"a8c637a81373a2c0bb56210beaaa93028ac497f1bb7561d46256bc2d67c3f289","cross_cats_sorted":[],"license":"http://creativecommons.org/licenses/by/4.0/","primary_cat":"stat.ME","submitted_at":"2018-03-12T17:47:00Z","title_canon_sha256":"0b8c9f1532d538f93166f74637f82cd6950933ac2d5f1e6501723e224ec5652e"},"schema_version":"1.0","source":{"id":"1803.04397","kind":"arxiv","version":2}},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1803.04397","created_at":"2026-05-18T00:13:04Z"},{"alias_kind":"arxiv_version","alias_value":"1803.04397v2","created_at":"2026-05-18T00:13:04Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1803.04397","created_at":"2026-05-18T00:13:04Z"},{"alias_kind":"pith_short_12","alias_value":"RVQHNDQNUI2R","created_at":"2026-05-18T12:32:50Z"},{"alias_kind":"pith_short_16","alias_value":"RVQHNDQNUI2RN5CD","created_at":"2026-05-18T12:32:50Z"},{"alias_kind":"pith_short_8","alias_value":"RVQHNDQN","created_at":"2026-05-18T12:32:50Z"}],"graph_snapshots":[{"event_id":"sha256:b8fd8d654d72f042d2b2f3db3bd06b8efeafaeb29ce13769d09f3dfd8c43aab0","target":"graph","created_at":"2026-05-18T00:13:04Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"graph_snapshot":{"author_claims":{"count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","strong_count":0},"builder_version":"pith-number-builder-2026-05-17-v1","claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"paper":{"abstract_excerpt":"For many years Phase I and Phase II clinical trials were conducted separately, but there was a recent shift to combine these Phases. While a variety of Phase~I/II model-based designs for cytotoxic agents were proposed in the literature, methods for molecularly targeted agents (TA) are just starting to develop. The main challenge of the TA setting is the unknown dose-efficacy relation that can have either an increasing, plateau or umbrella shape. To capture these, approaches with more parameters are needed to model the dose-efficacy relationship or, alternatively, more orderings of the dose-eff","authors_text":"Pavel Mozgunov, Thomas Jaki","cross_cats":[],"headline":"","license":"http://creativecommons.org/licenses/by/4.0/","primary_cat":"stat.ME","submitted_at":"2018-03-12T17:47:00Z","title":"An information-theoretic Phase I/II design for molecularly targeted agents that does not require an assumption of monotonicity"},"references":{"count":0,"internal_anchors":0,"resolved_work":0,"sample":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1803.04397","kind":"arxiv","version":2},"verdict":{"created_at":null,"id":null,"model_set":{},"one_line_summary":"","pipeline_version":null,"pith_extraction_headline":"","strongest_claim":"","weakest_assumption":""}},"verdict_id":null}}],"author_attestations":[],"timestamp_anchors":[],"storage_attestations":[],"citation_signatures":[],"replication_records":[],"corrections":[],"mirror_hints":[],"record_created":{"event_id":"sha256:ac2dc5b4cd7e1b314c077c4d3fdd65093d8296b6ce23792b0648b81e92893625","target":"record","created_at":"2026-05-18T00:13:04Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"attestation_state":"computed","canonical_record":{"metadata":{"abstract_canon_sha256":"a8c637a81373a2c0bb56210beaaa93028ac497f1bb7561d46256bc2d67c3f289","cross_cats_sorted":[],"license":"http://creativecommons.org/licenses/by/4.0/","primary_cat":"stat.ME","submitted_at":"2018-03-12T17:47:00Z","title_canon_sha256":"0b8c9f1532d538f93166f74637f82cd6950933ac2d5f1e6501723e224ec5652e"},"schema_version":"1.0","source":{"id":"1803.04397","kind":"arxiv","version":2}},"canonical_sha256":"8d60768e0da23516f4435b5698c7f17436a8635fccc884c81e7ae04ebdf1bf7b","receipt":{"algorithm":"ed25519","builder_version":"pith-number-builder-2026-05-17-v1","canonical_sha256":"8d60768e0da23516f4435b5698c7f17436a8635fccc884c81e7ae04ebdf1bf7b","first_computed_at":"2026-05-18T00:13:04.450429Z","key_id":"pith-v1-2026-05","kind":"pith_receipt","last_reissued_at":"2026-05-18T00:13:04.450429Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","receipt_version":"0.3","signature_b64":"jIYlXrPDTZxmiCeZCp+nfefnNdnUzLUNErMi8meTmnQKSJXu1EX4dAbWo87qaP2oDN+qUMbmmdXMvGk18Ge7Bw==","signature_status":"signed_v1","signed_at":"2026-05-18T00:13:04.451074Z","signed_message":"canonical_sha256_bytes"},"source_id":"1803.04397","source_kind":"arxiv","source_version":2}}},"equivocations":[],"invalid_events":[],"applied_event_ids":["sha256:ac2dc5b4cd7e1b314c077c4d3fdd65093d8296b6ce23792b0648b81e92893625","sha256:b8fd8d654d72f042d2b2f3db3bd06b8efeafaeb29ce13769d09f3dfd8c43aab0"],"state_sha256":"31b3573a8421cd5bbc3115046d7d1f626a768defa3ed89d37efda141732593f9"},"bundle_signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"dW0BMJ/t0/rjEOJ6ru16VbB/9gmNhp5O0M9iMolaYU69tVOdpg0IK9TVl3PWagl0+6wYo3ULDag4Sn/YKr4AAw==","signed_message":"bundle_sha256_bytes","signed_at":"2026-06-08T17:16:55.424607Z","bundle_sha256":"c307a945a61caf8b250b2209f8b0e8857d1c77cc891ecde4650fc353f31a8945"}}